Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma

Inclusion Criteria: * Male or female aged 15\~65 years * Written informed consent provided * Total serum IgE \>=60IU/ml * Duration of allergic asthma \>= 1 year according to GINA(2008) * Poor response to moderate to high dose inhaled corticosteroid (400ug/day\~800ug/day) \>= 4 weeks * Agreed to be not pregnant, contraception during study and later 6 months. Exclusion Criteria: Patients who met the below criteria were excluded: * Be regular smokers(\>10 cigarettes per day and for at least 2 years) * Patients who are currently pregnant or nursing or intend to become pregnant over the course of the study or later 6 months * COPD, according to the guideline of Chinese society of respiratory diseases * An active lung disease other than allergic asthma * Patients with significant underlying medical conditions * Allergic to immunoglobin or any formulation ingredient of the product * Patients with diabetes or uncontrolled hypertension(Systolic blood pressure\>160mmHg or Diastolic blood pressure\>95mmHg) * HIV positivity or cancer patient * Prior exposure to Xolair